Comparative Pharmacology
Head-to-head clinical analysis: DEXMETHYLPHENIDATE HYDROCHLORIDE versus EVEKEO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXMETHYLPHENIDATE HYDROCHLORIDE versus EVEKEO.
DEXMETHYLPHENIDATE HYDROCHLORIDE vs EVEKEO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexmethylphenidate is a central nervous system (CNS) stimulant. Its mechanism of action in ADHD is not fully understood, but it is believed to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
EVEKEO (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobin formation, which binds free cyanide. Sodium thiosulfate provides a sulfur donor for conversion of cyanide to thiocyanate via rhodanese.
Initial: 5 mg orally twice daily (morning and noon) with or without food; titrate in increments of 5 mg weekly; maximum 20 mg twice daily (40 mg/day).
5 mg IV infused over 1 hour every 2 weeks until disease progression or unacceptable toxicity. Reduce dose for adverse reactions.
None Documented
None Documented
2-4 hours (immediate-release); 4-5 hours (extended-release); clinical context: short half-life necessitates multiple daily dosing for immediate-release formulations
Terminal elimination half-life: 2-3 hours. Clinical context: Short half-life supports multiple daily dosing for seizure control. May be prolonged in hepatic impairment.
Renal (78-97% as metabolites and unchanged drug, with approximately 50% as de-esterified metabolites and 30% as unchanged drug)
Renal: 30-50% as unchanged drug; fecal: 50-70% as metabolites and unchanged drug.
Category A/B
Category C
CNS Stimulant
CNS Stimulant